ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral ...

Oncosol, along with its partner Shorla Oncology, has received US Food and Drug Administration (USFDA) approval for IMKELDI (imatinib oral solution) to treat leukemia and other cancers.

Shilpa Medicare's Joint Venture Oncosol, along with its partner Shorla Oncology, on Wednesday announced that the US FDA has ...

FDA has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor for treating leukemia and a range of cancers, including CML, GIST, and Ph+ ALL. Developed by Shorla Oncology ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Imkeldi is supplied as a strawberry-flavored oral solution in a 140 mL, child-resistant, tamper-evident bottle.

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.